業績紹介

2009年 論文

  • Are predictive models for cancer volume clinically useful in localized prostate cancer?
    Ishida M, Nakashima J, Hashiguchi A, Mizuno R, Shinoda K, Kikuchi E, Miyajima A, Nakagawa K, Mukai M, Oya M.
    Int J Urol. 2009 Dec;16(12):936-40.
  • Brain metastasis of a papillary renal cell carcinoma, identified as type 2.
    Hasegawa M, Kikuchi E, Yasumizu Y, Hattori S, Takeda T, Morita S, Kosaka T, Miyajima A, Horiguchi T, Mikami S, Oya M.
    Int J Clin Oncol. 2009 Jun;14(3):270-2.
  • Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer.
    Miyajima A, Kikuchi E, Kosaka T, Oya M.
    Rev Recent Clin Trials. 2009 May;4(2):75-8. Review.
  • Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y.
    J Pathol. 2009 Aug;218(4):530-9.
  • Renal damage inhibited in mice lacking angiotensinogen gene subjected to unilateral ureteral obstruction.
    Uchida Y, Miyajima A, Kikuchi E, Kozakai N, Kosaka T, Ieda M, Fukuda K, Ohigashi T, Oya M.
    Urology. 2009 Oct;74(4):938-43.
  • Renal cell carcinoma: biological features and rationale for molecular-targeted therapy.
    Oya M.
    Keio J Med. 2009 Mar;58(1):1-11. Review.
  • Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer.
    Kanai K, Nakashima J, Sugawara A, Shigematsu N, Nagata H, Kikuchi E, Miyajima A, Nakagawa K, Kubo A, Oya M.
    Int J Clin Oncol. 2009 Dec;14(6):502-6.
  • Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R, Nakashima J, Mukai M, Okita H, Kosugi M, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M. BJU Int. 2009 Nov;104(9):1215-8.
  • Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence.
    Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, Oya M.
    Urology. 2009 Jun;73(6):1318-22.
  • Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T; Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol. 2009 Mar;16(3):279-86.
  • Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
    Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M, Oya M.
    Urology. 2009 Mar;73(3):655-60.
  • Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
    Kanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M.
    J Urol. 2009 Feb;181(2):480-5; discussion 485.
  • Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.
    Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernandez MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF.
    J Clin Oncol. 2009 Feb 1;27(4):612-8.
業績紹介